|
Endo tips
Better Endo
New additions
Endo abstracts
Back to home page
Endo discussions
|
The opinions within this web page are not ours. Authors have been given due credit |
Preventing Bacterial Biofilm Formation
From: "Stephen Millar"
To: "Periotherapist group
Sent: Wednesday, February 06, 2008 2:01 AM
Subject: [periotherapist] Preventing Bacterial Biofilm Formation
About Biosignal and the anti-biofilm technology
Biosignal’s anti-biofilm technology is based on a discovery that the
eastern Australian seaweed Delisea pulchra produces natural furanones
that disable bacteria's ability to colonise. The fundamental problem
with existing anti-bacterials, including antibiotics, is bacterial
resistance. Bacteria rapidly produce resistant strains when faced
with strong selective pressure by
killing agents or growth-inhibitory agents. Furanones lull bacteria
to inaction and appear to avoid the problem of bacterial resistance.
Biosignal produces synthetic compounds effective on inanimate
surfaces such as pipes and membranes and animate surfaces such as
lungs, skin and teeth. Biosignal’s collaborations with US, European
and Japanese companies are assessing new applications across a range
of consumer and industrial products.
ASX Announcement
Biosignal compounds in dental material reduce bacteria by 99%
US entrepreneurs fund University of Minnesota study
4th of February 2008, Sydney: Laboratory testing using Biosignal
Ltd’s (ASX: BOS) anti-bacterial compounds in dental material found
Biosignal’s compounds reduce bacteria by more than 99 percent. The
material tested was a commercially used resin composite dental
material commonly used to restore tooth decay.
The work was commissioned and paid for by two entrepreneurial US-
based oral care experts Dr Gary Jernberg and Dr Richard Simonsen. The
pair has an agreement with Biosignal to assess commercial potential
of Biosignal’s compounds in selected oral care applications.
The study, announced to the market in March 2007 when it was
initiated, was conducted by the University of Minnesota, School of
Dentistry which is internationally recognised as a leader in oral
microbiology and prevention of oral disease including tooth decay and
periodontal disease.
This is a field in which there are no satisfactory products on the
market, said Peter Steinberg, CEO of Biosignal.
Our main competitors are traditional antibiotics, which are becoming
increasingly compromised by super bugs resistant and highly
dangerous bacteria. Biosignal’s compounds work by stopping bacterial
communication and preventing bacterial biofilm formation rather than
killing bacteria. This technique is not aggressive and should
minimise the problem of resistance while remaining effective.
Importantly, Biosignal's compounds were covalently bound to the
resin composite dental material with no measurable leaching from the
composite. This should significantly reduce regulatory timelines at
the US FDA or equivalent agencies.
Biosignal owns all intellectual property arising from the project.
Jernberg, Simonsen and Biosignal are commencing discussions to
license the technology to leading dental product companies. Further
animal and human trials are expected to be conducted in collaboration
with a licensee.
The bacterium tested was Streptococcus mutans which causes tooth
decay. The concentration of Biosignal’s compounds in the dental
material ranged up to a maximum of 3 percent of the total mass. The
testing also assessed impacts on the mechanical properties of the
dental material. No adverse effects of any expected clinical
significance were identified.
| 
